Density of clinical trial sites (per million people) by country, ranked by average annual trial density 2006–2012.

<p>Density of clinical trial sites (per million people) by country, ranked by average annual trial density 2006–2012.</p

Clinical trials by economic development status, 2006–2012.

<p>Clinical trials by economic development status, 2006–2012.</p

Proportion distribution of registered clinical trials among phase 2 studies by World Bank economic development category.

<p>Data for the United States and other high-income OECD countries are displayed separately.</p

Proportion distribution of registered clinical trials among phase 3 studies by World Bank economic development category.

<p>Data for the United States and other high-income OECD countries are displayed separately.</p

Proportion distribution of registered clinical trials among phase 1 studies by World Bank economic development category.

<p>Data for the United States and other high-income OECD countries are displayed separately.</p

Average annual clinical trial site growth rate by country, ranked by average annual growth rate 2006–2012.

<p>Average annual clinical trial site growth rate by country, ranked by average annual growth rate 2006–2012.</p

Total annual number of registered clinical trial sites beginning a study by World Bank economic development category.

<p>Data for the United States and other high-income OECD countries are displayed separately. Organization-sponsored funding sources included individuals, universities, foundations, and community-based organizations.</p

Number of cases of STDs reported by PREVEN Network.

<p>The number of cases of urethral discharge, vaginal discharge, genital ulcer disease, and pelvic inflammatory disease reported by the PREVEN Network of pharmacies or boticas for 2004, 2005, and 2006 was substantially higher than the numbers reported by Network physicians and midwives, especially for urethral discharge, less so for suspected PID.</p

Baseline census and training of pharmacy/botica workers, physicians and midwives in private practice in the 10 intervention cities.

*<p>Certification required attendance at all four seminars and passing the peer evaluation test and at least 60% correct answers to the written test.</p>**<p>Certification required attendance at two seminars, completion of homework and at least 60% correct answers to the written test.</p

Results of evaluations by Simulated Patients.

<p>Evaluations to pharmacy workers at baseline both at intervention and control cities showed no significant differences in STD management or referral, or in recommendations for use of condoms or partner treatment. Subsequent evaluations at three, six and 18 months showed significantly better performance for all measures in intervention cities.</p